Skip to main content
. Author manuscript; available in PMC: 2023 Oct 24.
Published in final edited form as: Clin Cancer Res. 2022 Dec 1;28(23):5088–5097. doi: 10.1158/1078-0432.CCR-22-2164

Figure 3.

Figure 3.

Partial responses in two patients in cohort D (nivolumab 3mg/kg plus ipilimumab 1mg/kg. A) Partial response in rhabdomyosarcoma after 4th cycle B) Partial response in Ewing sarcoma after 3rd cycle. C) Immunohistochemistry demonstrates infrequent PD-L1+ cells in Ewing sarcoma tumor tissue from diagnosis.